Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.
Rugo HS, Finn RS, Diéras V, Ettl J, Lipatov O, Joy AA, Harbeck N, Castrellon A, Iyer S, Lu DR, Mori A, Gauthier ER, Bartlett CH, Gelmon KA, Slamon DJ. · 2019
Read Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. by Rugo HS, Finn RS, Diéras V, Ettl J, Lipatov O, Joy AA, Harbeck N, Castrellon A, Iyer S, Lu DR, Mori A, Gauthier ER, Bartlett CH, Gelmon KA, Slamon DJ. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6438948.txt.
Introduction
Rugo and co-authors report extended follow-up of PALOMA-2, the phase 3 trial of palbociclib plus letrozole as first treatment for advanced ER-positive, HER2-negative breast cancer. Postmenopausal women who had no prior systemic therapy for advanced disease were randomized two to one, 444 to the combination and 222 to letrozole with placebo.
After a median follow-up near 38 months, median progression-free survival reached 27.6 months with palbociclib against 14.5 months without it. Every subgroup benefited, the gain carried into later therapy lines, and chemotherapy was delayed from 29.9 to 40.4 months. Side effects matched the known profile and quality of life held steady, supporting the pair as standard first-line care.
Catalog record
| CREATOR | Rugo HS, Finn RS, Diéras V, Ettl J, Lipatov O, Joy AA, Harbeck N, Castrellon A, Iyer S, Lu DR, Mori A, Gauthier ER, Bartlett CH, Gelmon KA, Slamon DJ. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up By H S Rugo, R S Finn, V Diéras, J Ettl, O Lipatov, A A Joy, N Harbeck, A Castrellon, S Iyer, D R Lu, A Mori, E R Gauthier Published in: Breast Cancer Research and Treatment DOI: 10.1007/s10549-018-05125-4 ABSTRACT Abstract Purpose In the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23 months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC) [hazard ratio (HR) 0.58; P < 0.001]. Herein, we report results overall and by subgroups with extended follow-up. Methods In this double-blind, phase 3 study, post-menopausal women with ER+/HER2− ABC who had not received prior systemic therapy for their advanced disease were randomized 2:1 to palbociclib-letrozole or placebo-letrozole. Endpoints include investigator-assessed PFS (primary), safety, and patient-reported outcomes (PROs). Results After a median follow-up of approximately 38 months, median PFS was 27.6 months for palbociclib–letrozole (n = 444) and 14.5 months for placebo-letrozole (n = 222) (HR 0.563; 1-sided P < 0.0001). All subgroups benefited from palbociclib treatment. The improvement of PFS with palbociclib-letrozole was maintained in the next 2 subsequent lines of therapy and delayed the use of chemotherapy (40.4 vs. 29.9 months for palbociclib–letrozole vs. placebo-letrozole). Safety data were consistent with the known profile. Patients’ quality of life was maintained. Conclusions With approximately 15 months of additional follow-up, palbociclib plus letrozole continued to demonstrate improved PFS compared with placebo plus letrozole in the overall population and across all patient subgroups, while the safety profile remained favorable and quality of life was maintained. These data confirm that palbociclib-letrozole should be considered the standard of care for first-line therapy in patients with ER+/HER2− ABC, including those with low disease burden or long disease-free interval. Sponsored by Pfizer; ClinicalTrials.gov: NCT01740427. Electronic supplementary material The online version of this article (10.1007/s10549-018-05125-4) contains supplementary material, which is available to authorized users. Keywords: Breast cancer, ER+, HER2−, Cyclin-dependent kinase inhibitor, Palbociclib, Letrozole INTRODUCTION Endocrine therapy has been the primary first-line treatment for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC) [1–3]. Recently, guidelines have expanded to include the addition of a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in combination with endocrine therapy for the treatment of pre-menopausal/post-menopausal women with HR+/HER2‒ ABC [1–3]. In the PALOMA-2 study, palbociclib-letrozole significantly prolonged progression-free survival (PFS) versus placebo-letrozole [median PFS, 24.8 vs. 14.5 months, respectively; hazard ratio [HR], 0.576 (95% CI 0.463–0.718); P < 0.0001] [4, 5]. The primary analysis was conducted after a median 23 months of follow-up (data cut-off: February 26, 2016), with the investigators and patients remaining blinded to treatment assignments. Because patients with HR+/HER2− ABC receiving first-line therapy have diverse clinical and molecular presentations (e.g., de novo versus recurrent disease, visceral versus bone-only), response to endocrine-based therapy could be prolonged in a particular subgroup. Therefore, it is important to analyze the long-term efficacy of treatment with extended follow-up in different patient subgroups. Currently, PALOMA-2 has the longest follow-up of any phase 3 study investigating CDK4/6 inhibitors for HR+/HER2− disease. In this report, we present updated efficacy, safety, and patient-reported outcome (PRO) results for the overall PALOMA-2 study population and across subgroups after extended patient follow-up. This study is ongoing to collect overall survival data. METHODS Study design, treatment, and patient eligibility criteria Eligibility criteria and study design details were reported previously [4]. PALOMA-2 was a double-blind, international, phase 3 study in which women with estrogen receptor-positive (ER+)/HER2− advanced breast cancer were randomized 2:1 to receive letrozole 2.5 mg/day continuously and either palbociclib (125 mg/day, 3 weeks on followed by 1 week off of a 4-week cycle) or matching placebo. The study protocol was reviewed and approved by institutional review boards/independent ethics committees at each site (Table S1) and was conducted in accordance with Good Clinical Practice principles and the Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study. Endpoints and assessments The study’s primary endpoint was investigator-assessed PFS, defined as the time from date of randomization to the date of first documented objective disease progression (per Response Evaluation Criteria in Solid Tumors, v1.1) or death due to any cause, whichever occurred first. A blinded, independent central review of all patients was performed in a third party facility. Secondary endpoints included patient-reported outcomes (PROs), pharmacokinetics, and safety assessments. Subgroup analyses by baseline characteristics were pre-specified. Patient-reported breast cancer-specific health-related quality of life (HRQOL) was assessed using the Functional Assessment of Cancer Therapy-Breast (FACT-B) completed on-site at baseline (day 1 of cycle 1), day 1 of cycles 2 and 3, and day 1 of every other cycle from cycle 5 until progression or end of treatment [6–8]. Adverse events (AEs) were recorded during study treatment until 28 days after the last treatment dose. AEs were graded for severity according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 and classified according to Medical Dictionary for Regulatory Activities (MedDRA, v20.0). In addition to these endpoints, time to initiation of subsequent anticancer therapies (including chemotherapy) was assessed in the overall study population as an exploratory analysis to investigate whether palbociclib–letrozole treatment affected subsequent therapies. The time to initiation of subsequent therapy was defined as the time from randomization to the start date of subsequent systemic anticancer therapy or death from any cause, whichever occurred first. Statistical analyses Progression-free survival was evaluated in the overall intent-to-treat (ITT) population and in preplanned subgroups defined by their baseline characteristics. Time to subsequent therapies was evaluated in the ITT population. The Kaplan–Meier method was used to estimate median PFS and time to subsequent systemic anticancer therapies (including chemotherapy) by treatment arm. Hazard ratios for PFS and time to first and second subsequent systemic anticancer therapies were estimated from the Cox proportional hazards model with a 95% CI; 1-sided P values were from the log-rank test. No adjustments were made for multiple testing. Repeated-measures mixed effects models were used to assess the effect on changes from baseline in patient-reported quality of life using intercept term, treatment, time, treatment-by-time, and baseline as covariates. A subpopulation treatment effect pattern plot (STEPP) [9] analysis was performed to explore whether PFS benefit was affected by a patient’s treatment-free interval (TFI) at baseline, where TFI (equivalent to the protocol-defined disease-free interval [DFI]) was defined as the time from the end of (neo)adjuvant therapy to disease progression. AE data were analyzed for patients who received ≥ 1 dose of study drug. RESULTS Patients From February 2013 through July 2014, 666 post-menopausal women were enrolled and randomly assigned to receive palbociclib-letrozole (n = 444) or placebo-letrozole (n = 222) (Fig. S1). Demographics and baseline disease characteristics were well balanced between treatment arms and similar to that previously reported [4] (Table S2). Exposure to palbociclib or placebo is summarized in Table S3. Efficacy At the new data cut-off date (May 31, 2017), median (interquartile range) follow-up was 37.6 (37.2–38.0) months in the palbociclib-letrozole arm and 37.3 (36.3–37.9) months in the placebo-letrozole arm. Investigator-assessed PFS was significantly longer with palbociclib-letrozole versus placebo-letrozole in the ITT population, with a median of 27.6